Elbasvir

• CAT Number: I001427
• CAS Number: 1370468-36-2
• Molecular Formula: C49H55N9O7
• Molecular Weight: 882.02
• Purity: 98%
• Target: HCV
• Target Protein: Q5L478,B0B3C9
• Solubility: 10 mM in DMSO
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: EC50: 4nM(genotype 1a), 3nM(genotype 1b) and 3nM(genotype 2a)
• IUPAC Name: methyl N-[(2S)-1-[(2S)-2-[5-[(6S)-3-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
• InChI: InChI=1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1
• InChIKey: BVAZQCUMNICBAQ-PZHYSIFUSA-N
• SMILES: CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC4=C(C=C3)N5[C@@H](OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@H](C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC

Elbasvir (Cat No.:I001427) is a direct-acting antiviral (DAA) medication used for the treatment of chronic hepatitis C virus (HCV) infection. It is a potent and selective inhibitor of the HCV non-structural protein 5A (NS5A), which plays a critical role in viral replication and assembly. Elbasvir interferes with NS5A’s function, inhibiting HCV replication and reducing viral load. When used in combination with other DAAs, such as grazoprevir, it has shown high sustained virologic response rates across different HCV genotypes, making it an effective treatment option for patients with chronic HCV infection. Elbasvir-based regimens have significantly improved the outcomes of HCV therapy, offering a more convenient and effective alternative to traditional interferon-based treatments.

Reference

1: Elbasha EH, Ferrante S, Agarwal E, Greaves W, Nwankwo C. Projected Clinical

And Economic Impact Of Grazoprevir (Gzr, Mk-5172)/Elbasvir (Ebr, Mk-8742) For

Chronic Hcv Genotype 1 Infection In Chronic Kidney Disease. Value Health. 2015

Nov;18(7):A510. doi: 10.1016/j.jval.2015.09.1469. Epub 2015 Oct 20. PubMed PMID:

26532861.

2: Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews

GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen

BY, Barr E, Platt HL, Robertson MN, Sulkowski M. Efficacy and safety of

grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus

and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

Lancet HIV. 2015 Aug;2(8):e319-27. doi: 10.1016/S2352-3018(15)00114-9. Epub 2015

Jul 9. Erratum in: Lancet HIV. 2015 Aug;2(8):e316. Lancet HIV. 2015

Oct;2(10):e416. PubMed PMID: 26423374.

3: Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L,

Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko

F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B.

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir

(MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus

genotype 1 infection in previously untreated patients with cirrhosis and patients

with previous null response with or without cirrhosis (C-WORTHY): a randomised,

open-label phase 2 trial. Lancet. 2015 Mar 21;385(9973):1075-86. doi:

10.1016/S0140-6736(14)61795-5. Epub 2014 Nov 11. Erratum in: Lancet. 2015 Mar

21;385(9973):1074. PubMed PMID: 25467591.

4: Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M,

Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E,

Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr

E, Haber B. Efficacy and safety of 8 weeks versus 12 weeks of treatment with

grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in

patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C

virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet.

2015 Mar 21;385(9973):1087-97. doi: 10.1016/S0140-6736(14)61793-1. Epub 2014 Nov

11. PubMed PMID: 25467560.